Atmosphere-ph.ru

Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Телефон издательства

Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 2

Клиническая эффективность муколитической терапии амброксолом у детей
Ю.Л. Мизерницкий

References

1. Mizernitskiy YuL. Childhood pulmonology: advances, tasks, and prospects. Russian Bulletin of Perinatology and Pediatrics 2014;59(2):4-10 (In Russian).
2. Mizernitskiy YuL, Melnikova IM. Mucolytic and expectorant pharmacotherapy in paediatric lung diseases. Moscow: Medpraktika-M; 2013. 120 p. (In Russian).
3. Misernitskiy YuL, Melnikova IM. Differentiation mucolytic therapy in acute and chronic bronchopulmonary diseases in pediatric practice. Russian Bulletin of Perinatology and Pediatrics 2016;61(4):23-30 (In Russian).
4. Misernitskiy YuL, Melnikova IM, Udaltsova EV. Differential diagnosis of prolonged and chronic cough in children. Consilium Medicum 2017;19(11.1):7-16 (In Russian).
5. Mucoactive therapy. Chuchalin AG, Belevskiy AS, editors. Moscow: ID Atmosphera; 2006. 128 p. (In Russian).
6. Respiratory medicine: guidelines. Chuchalin AG, editor. Moscow: Geotar-Media; 2007. 1616 p. (In Russian).
7. Mizernitskiy YuL. Expectorants and mucolytic agents in therapy of bronchopulmonary diseases in children. In: Guidelines to pharmacotherapy in pediatrics and pediatric surgery. Tsaregorodtsev AD, Tabolin VA, editors. 8-vol. set. Vol. 1. Pharmacotherapy in pediatric pulmonology. Kaganov SYu, editor. Moscow: Medpraktika-M; 2002: 123-40 (In Russian).
8. Samsygina GA. Cough treatment in children. GN Speranskiy Journal of Pediatria 2004;83(3):84-92 (In Russian).
9. Melnikova IM, Mizernitskiy YuL, Batozhargalova BTs, Loginevskaya YaV. Mucolytic therapy in children with acute and chronic bronchopulmonary diseases. Russian Bulletin of Perinatology and Pediatrics 2011;56(2):45-9 (In Russian).
10. Zaytseva OV, Bardenikova SI, Zaytseva SV, Rychkova TI, Lokshina EE. Current aspects of pathogenetic cough therapy in children. Lechashchiy Vrach 2010;2:60-8 (In Russian).
11. Revyakina VA. Cough in children: causes and approaches to therapy. Consilium Medicum. Pediatrics 2006;8(2):38-41 (In Russian).
12. Simonova OI. Administration of mucolytics with direct action in pediatric practice. Current Pediatrics 2011;10(1):153-9 (In Russian).
13. Dvoretskiy LI. Cough: differential diagnosis. Consilium Medicum 2006;8(3):5 (In Russian).
14. Kazachkov M. Etiology and differential diagnosis of chronic cough in children. Russian Bulletin of Perinatology and Pediatrics 2013;58(3):54-61 (In Russian).
15. Sinopalnikov AI, Klyachkina IL. Cough: differential diagnosis and differential treatment. Therapeutic Archive 2012;84(8):95-102 (In Russian).
16. Snimshchikova IA, Medvedev AI, Krasnikov VV. Cough in children: a current view. Difficult Patient 2004;9(2):42-6 (In Russian).
17. Zamotayev IP. Pharmacotherapy in pulmonology. Moscow: Interbook; 1993. 262 p. (In Russian).
18. Zykov KA. Prospects of ambroxol application in the United States. Spravochnik Poliklinicheskogo Vracha 2009;3:36-8 (In Russian).
19. Vasilenko IA. Drug interchangeability: comparative aspects. Drug Development & Registration 2014;1(6):146-52 (In Russian).
20. Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Respiratory Research 2012 Oct;13:98.
21. Orlov AV, Ghembitskaya TE. Bronchial secretion: formation, excretion and drug impact. Allergologiya 1999;4:37-42 (In Russian).
22. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respiratory Care 2007 Jul;52(7):859-65.
23. Bianchi M, Mantovani A, Erroi A, Dinarello CA, Ghezzi P. Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells. Agents and Actions 1990 Nov;31(3-4):275-9.
24. Varelogianni G, Oliynyk I, Roomans GM, Johannesson M. The effect of N-acetylcysteine on chloride efflux from airway epithelial cells. Cell Biology International 2010 Jan;34(3):245-52.
25. Ottonello L, Arduino N, Bertolotto M, Dapino P, Mancini M, Dallegri F. In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism. British Journal of Pharmacology 2003 Oct;140(4):736-42.
26. Zhi QM, Yang LT, Sun HC. Protective effect of ambroxol against paraquat-induced pulmonary fibrosis in rats. Internal Medicine 2011;50(18):1879-87.
27. Pairet M, Engelmann P, Von Nicolai H, Champeroux P, Richard S, Rauber G, Engelhardt G. Ambroxol improves the broncho-spasmolytic activity of clenbuterol in the guinea-pig. The Journal of Pharmacy and Pharmacology 1997 Feb;49(2):184-6.
28. Pfeifer S, Zissel G, Kienast K, Müller-Quernheim J. European Journal of Medical Research 1997 Mar;2(3):129-32.
29. Gibbs BF, Schmutzler W, Vollrath IB, Brosthardt P, Braam U, Wolff HH, Zwadlo-Klarwasser G. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflammation Research: Official Journal of the European Histamine Research Society 1999 Feb;48(2):86-93.
30. Kido H, Okumura Y, Yamada H, Mizuno D, Higashi Y, Yano M. Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential. Biological Chemistry 2004 Nov;385(11):1029-34.
31. Zykov KA, Agapova OYu, Sokolov EI. New aspects for ambroxol application in the United States: impact on biofilm. Consilium Medicum 2014;1:27-32 (In Russian).
32. Zakharova IN, Dmitriyeva YuA. Efficacy of mucolytics in children’s cough treatment. Consilium Medicum Ukraina 2010;4(1):32-5 (In Russian).
33. Fan YZ, Wen ZL. [Efficacy of different dosages of ambroxol hydrochloride in the prevention of neonatal respiratory distress syndrome]. Zhongguo Dang Dai Er Ke Za Zhi 2009 Sep;11(9):771-2.
34. Baldini G, Gucci M, Tarò D, Memmini C. [A controlled study on the action of a new formulation of ambroxol in asthmatiform bronchitis in children]. Minerva Pediatrica 1989 Feb;41(2):91-5.
35. Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulmonary Pharmacology & Therapeutics 2004;17(1):27-34.
36. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opinion on Drug Metabolism & Toxicology 2008 Aug;4(8):1119-29.
37. Babak SL, Gorbunova MV, Malyavin AG. Rational mucolytic therapy in therapeutic practice. Farmateka 2018;3(356):52-9 (In Russian).
38. Knyazheskaya NP, Bobkov EV. Current mucolytic therapy of respiratory diseases. Russian Medical Journal 2018;3(I):30-5 (In Russian).
39. Klyachkina IL, Sinopalnikov AI. Ambroxol in treatment of chronic bronchopulmonary diseases. Practical Pulmonology 2018;2:83-92 (In Russian).
40. Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. American Family Physician 2012 Jul;86(2):153-9.
41. Wunderer H, Morgenroth K, Weis G. [The cleaning system of the airways: physiology, pathophysiology and effects of ambroxol]. Medizinische Monatsschrift für Pharmazeuten 2009 Feb;32(2):42-7.
42. Mizernitskiy YuL. Inhalation therapy of bronchopulmonary diseases in children and adults: current opportunities. In: Osipov LV, Zhilin YuN, Avdeyev SN, Mizernitskiy YuL. Ultrasonic and compressor inhalers (nebulizers) for treatment of respiratory and lung diseases. Moscow: Izomed; 2014. 105 p. (In Russian).
43. Simonova OI, Gorinova YuV. Inhalation therapy with ambroxol (Lasolvan®) solution: advantages, features of application, and efficacy. Russian Medical Journal 2014;22(21):1530-34 (In Russian).
44. Suárez-Castañón C, Modroño-Riaño G, López-Vilar P, Martínez-Blanco J, Iglesias-Cabo T, Solís-Sánchez G. [Use of cold and cough medications prescribed in Primary Care clinics for children less than 14 years]. Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.) 2016 Jan;84(1):10-7.
45. Chang CC, Cheng AC, Chang AB, Over‐the‐counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Systematic Review 2012;2:1465-858.
46. Kardos P, Dinh QT, Fuchs KH, Gillissen A, Klimek L, Koehler M, Sitter H, Worth H. [Guidelines of the German Respiratory Society for Diagnosis and Treatment of Adults Suffering from Acute, Subacute and Chronic Cough]. Pneumologie 2019 Mar;73(3):143-80.
47. Acute respiratory infection in children: diagnosis, treatment, and prevention. Clinical guidelines. Geppe NA, editor. Moscow: Medcom-Pro; 2018. 200 p. (In Russian).

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]